Insider Selling: Catalent Inc (CTLT) Insider Sells 47,265 Shares of Stock

Catalent Inc (NYSE:CTLT) insider Barry Littlejohns sold 47,265 shares of the stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $41.64, for a total value of $1,968,114.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

CTLT traded down $0.14 during trading on Friday, reaching $37.51. The stock had a trading volume of 1,133,400 shares, compared to its average volume of 857,435. The company has a market capitalization of $5.48 billion, a price-to-earnings ratio of 23.59, a price-to-earnings-growth ratio of 2.24 and a beta of 1.45. The company has a debt-to-equity ratio of 1.44, a current ratio of 2.05 and a quick ratio of 1.79. Catalent Inc has a 1-year low of $34.24 and a 1-year high of $47.87.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Tuesday, November 6th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.04. Catalent had a return on equity of 19.13% and a net margin of 2.65%. The company had revenue of $551.80 million during the quarter, compared to the consensus estimate of $582.44 million. During the same quarter in the prior year, the firm earned $0.21 EPS. The company’s quarterly revenue was up 1.5% compared to the same quarter last year. Equities analysts expect that Catalent Inc will post 1.72 EPS for the current fiscal year.

Several large investors have recently made changes to their positions in CTLT. Summit Trail Advisors LLC lifted its position in shares of Catalent by 2,021.9% during the 1st quarter. Summit Trail Advisors LLC now owns 103,210 shares of the company’s stock valued at $103,000 after acquiring an additional 98,346 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC acquired a new stake in shares of Catalent during the 2nd quarter valued at $145,000. Moneta Group Investment Advisors LLC lifted its position in shares of Catalent by 105.0% during the 2nd quarter. Moneta Group Investment Advisors LLC now owns 3,515 shares of the company’s stock valued at $147,000 after acquiring an additional 1,800 shares during the last quarter. CIBC Asset Management Inc acquired a new stake in shares of Catalent during the 3rd quarter valued at $217,000. Finally, Hartford Investment Management Co. acquired a new stake in shares of Catalent during the 2nd quarter valued at $220,000. Institutional investors own 92.08% of the company’s stock.

A number of equities analysts recently issued reports on CTLT shares. TheStreet lowered Catalent from a “b-” rating to a “c+” rating in a report on Wednesday. Royal Bank of Canada set a $44.00 price objective on Catalent and gave the stock a “buy” rating in a report on Wednesday. ValuEngine lowered Catalent from a “buy” rating to a “hold” rating in a report on Tuesday. Zacks Investment Research raised Catalent from a “sell” rating to a “hold” rating in a report on Monday, October 1st. Finally, First Analysis raised Catalent from a “neutral” rating to an “outperform” rating and decreased their price objective for the stock from $47.00 to $43.00 in a report on Wednesday. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Catalent presently has an average rating of “Buy” and an average price target of $48.11.

WARNING: “Insider Selling: Catalent Inc (CTLT) Insider Sells 47,265 Shares of Stock” was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.baseballdailydigest.com/2018/11/10/barry-littlejohns-sells-47265-shares-of-catalent-inc-ctlt-stock.html.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Featured Article: Capital gains and your 401(k) or IRA

Insider Buying and Selling by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply